Seattle biotech company Blaze Bioscience has received Fast Track designation from the FDA for a clinical program evaluating tozuleristide.
Update, April 8: Blaze confirmed that it recently raised an additional $5 million, after raising $15 million in 2019.
Also known as BLZ-100, tozuleristide is what the company refers to as “Tumor Paint,” a molecule that binds to cancer cells and lights them up to help brain surgeons remove tumors.
Tumor Paint was created using a peptide, or a small protein, from the Israeli deathstalker scorpion.
“Pediatric brain tumors remain the leading cause of cancer-related death among children and adolescents,” Dr. Dennis Miller, Blaze Bioscience executive vice president of development, said in a statement.

Comments to: Blaze Bioscience gets Fast Track approval from FDA for ‘Tumor Paint’ that helps remove brain tumors

Your email address will not be published. Required fields are marked *

Attach images - Only PNG, JPG, JPEG and GIF are supported.


Welcome to Typer

Brief and amiable onboarding is the first thing a new user sees in the theme.
Join Typer
Registration is closed.